Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
Hodson L, Bhatia L, Scorletti E, Smith DE, Jackson NC, Shojaee-Moradie F, Umpleby M, Calder PC, Byrne CD
European journal of clinical nutrition · 49 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Institute for Health and Care Research
- Nonprofit
- British Heart Foundation
- Nonprofit
- Diabetes UK
- University or hospital
- National Institute for Health Research Southampton Biomedical Research Centre
- Government
- National Institute for Health Research (NIHR)
- Grants
- National Institute for Health and Care Research (SOUBRC-1); Diabetes UK (11/0004337); British Heart Foundation (FS/11/18/28633)
Based on 5 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2017-03-15 · Eur J Clin Nutr · vol. 71 · issue 8 · pp. 973–979
- Publisher
- Springer Nature
- Cited
- 65 citations · more than 97% of similar papers · 5.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 34 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Metabolomics and Mass Spectrometry Studies
- Keywords
- Postprandial, Internal medicine, Docosahexaenoic acid, Endocrinology, Fatty liver, Insulin resistance, Insulin, Lipogenesis, Triglyceride, Polyunsaturated fatty acid, Placebo, Medicine, Biology, Fatty acid, Lipid metabolism, Cholesterol, Biochemistry, Pathology, Disease
- MeSH
- liver, erythrocytes, humans, insulin resistance, 3-hydroxybutyric acid, docosahexaenoic acids, eicosapentaenoic acid, cohort studies, pilot projects, double-blind method, dietary supplements, adult, middle aged, female, male, lipogenesis, lipid metabolism, non-alcoholic fatty liver disease, biomarkers, proof of concept study
9 authors
From GB
- Leanne Hodson · correspondingUniversity of Oxford; Oxford Centre for Diabetes, Endocrinology and Metabolism
- Lokpal S. Bhatia
- Eleonora ScorlettiUniversity Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
- Debbie E. SmithUniversity Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
- Nicola C. JacksonUniversity of Surrey
- Fariba Shojaee‐MoradieUniversity of Surrey
Abstract
Background/objective
Treatment of subjects with non-alcoholic fatty liver disease (NAFLD) with omega-3 polyunsaturated fatty acids (FAs) suggests high levels of docosahexaenoic acid (DHA) tissue enrichment decrease liver fat content. We assessed whether changes in erythrocyte DHA enrichment (as a surrogate marker of changes in tissue enrichment) were associated with alterations in hepatic de novo lipogenesis (DNL), postprandial FA partitioning and hepatic and peripheral insulin sensitivity in a sub-study of the WELCOME trial (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD (non-alcoholic fatty liver disease) with OMacor thErapy).
Subjects/methods
Sixteen participants were randomised to 4 g/day EPA+DHA (n=8) or placebo (n=8) for 15-18 months and underwent pre- and post-intervention measurements. Fasting and postprandial hepatic FA metabolism was assessed using metabolic substrates labelled with stable-isotope tracers (2H2O and [U13C]palmitate). Insulin sensitivity was measured by a stepped hyperinsulinaemic-euglycaemic clamp using deuterated glucose. Participants were stratified according to change in DHA erythrocyte enrichment (< or ⩾2% post intervention).
Results
Nine participants were stratified to DHA⩾2% (eight randomised to EPA+DHA and one to placebo) and seven to the DHA13C from dietary fat into plasma 3-hydroxybutyrate (all P<0.05).
Conclusions
The findings from our pilot study indicate that individuals who achieved a change in erythrocyte DHA enrichment ⩾2% show favourable changes in hepatic FA metabolism and insulin sensitivity, which may contribute to decreasing hepatic fat content.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.